uniQure (NASDAQ:QURE) Given Average Rating of “Moderate Buy” by Analysts

Shares of uniQure (NASDAQ:QURE) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $32.00.

Several research analysts have recently issued reports on QURE shares. Royal Bank of Canada restated an “outperform” rating and issued a $28.00 target price on shares of uniQure in a report on Tuesday, January 16th. Mizuho cut their price target on shares of uniQure from $10.00 to $7.00 and set a “neutral” rating on the stock in a report on Monday, March 4th. The Goldman Sachs Group cut shares of uniQure from a “buy” rating to a “neutral” rating and cut their price target for the company from $63.00 to $8.00 in a report on Thursday, February 29th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Friday, March 1st. Finally, HC Wainwright cut their price target on shares of uniQure from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, March 1st.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the transaction, the chief executive officer now owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the transaction, the chief executive officer now owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 15,906 shares of uniQure stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.38, for a total value of $101,480.28. Following the completion of the transaction, the chief financial officer now directly owns 116,948 shares of the company’s stock, valued at approximately $746,128.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,265 shares of company stock valued at $339,845. 4.05% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Large investors have recently bought and sold shares of the business. BluePath Capital Management LLC bought a new stake in uniQure in the 3rd quarter worth about $27,000. Headlands Technologies LLC bought a new stake in uniQure in the 3rd quarter worth about $31,000. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 222.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after buying an additional 4,315 shares in the last quarter. Nomura Holdings Inc. bought a new stake in uniQure in the 3rd quarter worth about $67,000. Finally, Laurion Capital Management LP bought a new stake in uniQure in the 3rd quarter worth about $73,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Stock Up 0.2 %

Shares of uniQure stock opened at $4.69 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. uniQure has a 52-week low of $4.25 and a 52-week high of $22.48. The stock has a market capitalization of $224.36 million, a price-to-earnings ratio of -0.72 and a beta of 0.98. The company’s 50 day moving average price is $5.10 and its 200-day moving average price is $5.92.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.01. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. The firm had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $3.20 million. Equities research analysts forecast that uniQure will post -4.49 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.